High Court Asked To Weigh Inequitable Conduct Ruling

Law360, New York (January 29, 2009, 12:00 AM EST) -- Subsidiaries of Sanofi-Aventis have asked the U.S. Supreme Court to weigh in on a decision that upheld a lower court’s finding that Aventis’ patents for its anti-clotting drug Lovenox were invalid due to inequitable conduct.

Aventis Pharma SA and Aventis Pharmaceuticals Inc. filed a petition for a writ of certiorari with the Supreme Court on Jan. 23 that seeks to reverse the U.S. Court of Appeals for the Federal Circuit’s 2-1 opinion that affirmed a district court’s ruling in favor of generics makers Amphastar Pharmaceuticals Inc....
To view the full article, register now.